Natera, Inc. sees price target hike and new strategic partnership

Natera, Inc. has seen significant activity regarding its stock valuation and strategic partnerships. TD Cowen raised its price target for the medical research company from $340.00 to $480.00, maintaining a buy recommendation based on market potential and volume growth.

In a recent strategic move, Natera announced a collaboration with TransCode Therapeutics. The partnership aims to use Signatera to identify patients with molecular residual disease for a Phase 2a study of TTX-MC138 in colorectal cancer. This follows Natera receiving Breakthrough Device designation from the US FDA for its multi-cancer early detection blood test.

On the investment front, Sax Wealth Advisors LLC acquired 4,775 shares of Natera in the third quarter, valued at approximately $1,974,000. Other major institutional investors, including BlackRock Inc., Castle Hook Partners LP, and UBS AM, have also maintained or increased their positions in the company. Institutional investors and hedge funds currently own 99.90% of Natera's stock.